Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Feb 07, 2023 12:13pm
124 Views
Post# 35272017

RE:RE:RE:RE:RE:RE:Red Flags to Consider

RE:RE:RE:RE:RE:RE:Red Flags to Considercan't make sense out of your word salad.

i'm not implying anything about AN's physical property.  please provide something concrete which supports your position that a buyer of oncy could just walk away from the oncy/AN agreement.

i've provided actual language from the agreement which clearly states that oncy has the rights to pela in the "rest of the world".  the "rest of the world" is defined in the agreement as anyplace other than china, singapore, macau, taiwan, hong kong and south korea.  it's those six areas which i've said make up close to 20% of the world population (read market for pela and what ever combos might be clinically tried, applied for and approved in those markets).

you are very good about providing context about other things you post, not so much regarding this issue.  again, can you cite any language from the agreement which supports your position?

let's keep things real.  contract language is difficult at best but is written to cover things which are far from boilerplate provisions.  the meat of a contract/agreement is found in those words which are outside of the boilerplate.


<< Previous
Bullboard Posts
Next >>